Laurence Hicks, Director at Arch Therapeutics, Inc. (ARTH), bought 10,292 shares at $0.28 ($3K) on 2023-08-31, disclosed to the SEC on 2023-09-08.
Open-market purchase of $3k ARTH by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.